大麻酚
药品
大麻
药理学
工具箱
医学
药代动力学
计算机科学
精神科
程序设计语言
作者
Clémence Lacroix,Romain Guilhaumou,Joëlle Micallef,Olivier Blin
出处
期刊:Therapie
[Elsevier]
日期:2023-05-01
被引量:1
标识
DOI:10.1016/j.therap.2023.05.003
摘要
Cannabidiol (CBD) is one of the most important components of the Cannabis sativa plant with delta9-tetrahydrocannabinol (THC). CBD is used both for medical and recreational purposes. It can be of pharmaceutical grade (Epidyolex®), and also self-service purchased in pharmacy, CBD shops and on the internet (non-pharmaceutical). CBD is almost as widespread as it is poorly understood from a pharmacological point of view and particularly in terms of drug interactions. Drug-drug interactions could lead to clinical complications, and we here gather data currently available on pharmacokinetics (PK) drug-drug interactions with CBD through a narrative review. This review shows that several PK drug-drug interactions exist with different class of medications and aims to help clinicians to better know about CBD for their practice as this product is increasingly used.
科研通智能强力驱动
Strongly Powered by AbleSci AI